X

Trial Profile

A first-in-human study of RT011 for the treatment of dry age-related macular degeneration (AMD)

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 22 Oct 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Docosahexaenoic acid (Primary)
Indications Dry age-related macular degeneration
Focus Adverse reactions; First in man

Most Recent Events

19 Oct 2021 According to a Retrotope media release, the company expects to file an Investigational New Drug (IND) application for RT011 in the first half of 2022 and initiate first-in-human clinical studies in dry AMD soon thereafter.
02 Mar 2021 New trial record
11 Feb 2021 According to a Retrotope media release, the company expects to initiate this study in the mid-2021

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com